MTOR and nonpapillary renal cell carcinoma: With the discovery of genetic mutations in ccRCC, more influential molecules and signaling pathways (e.g., HIF-1/2, PBRM1, SETD1, BAP1 and PI3k/Akt/mTOR) have been revealed to participate in the proliferation, metastasis, and therapeutic targets this disease [16].